In our laboratory, seven novel kinesin Eg5 inhibitors (2, 4, 26, 30, 31, 41, and 44) were synthesized keeping constant the thiadiazoline core nucleus and modifying the C5 substituents of K858, the most common Eg5 inhibitor used in cancer therapies, due to their promising inhibition of the basal Eg5 ATPase activity (0.84 < IC50 (μM) < 7.5) in vitro [12]. This evidence concerns the gene KIF11 and cancer.